🇺🇸 FDA
Patent

US 11382981

Exon skipping oligomer conjugates for muscular dystrophy

granted A61KA61K47/549A61K47/645

Quick answer

US patent 11382981 (Exon skipping oligomer conjugates for muscular dystrophy) held by Sarepta Therapeutics, Inc. expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Jul 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K47/549, A61K47/645, A61P, A61P21/00